JPRN-UMIN000005774已完成未知
Justification for Atherosclerosis Regression Treatment [JART Extension Study] - JART [JART Extension Study]
Japan Atherosclerosis Regressive Treatment Study Group0 个研究点目标入组 400 人开始时间: 2011年6月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 400
研究概览
简要总结
ohara R et al. : Circ J. 2012;76(1): 221-229 Nohara R et al. : Circ J 2013; 77(6): 1526 -1533
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients that require lipid-lowering therapy other than the study drug or specified lipid-lowering drugs (anion-exchange resin, inhibitor of probucol, and ethyl icosapentate (EPA)) (2) Patients who have taken statins within one month before the start of the clinical trial. (3) Patients suspected of having serious carotid artery stenosis (greater than 80%) or having serious calcification. (4) Patients with familial hypercholesterolemia or secondary hypercholesterolemia. (5) Patients with fasting serum TG >= 400 mg/dL. (6) Patients with a history of sensitivity to statins. (7) Patients with uncontrolled hypertension. (8) Patients with Type I diabetes or uncontrolled Type II diabetes. (9) Patients who have experienced myocardial infarction or a cerebral stroke within 3 months or Patients with serious heart failure (NYHA class III to IV). (10) Patients with active hepatic disease. (11) Patients with renal disorder (Cr >= 2.0 mg/dL or Ccr < 30 mL/min/1.73m2). (12) Patients with CK > 500 IU/L. (13) Patients currently being treated with cyclosporine. (14) Patients that are pregnant or potentially pregnant, patients breast-feeding, or patients aiming to become pregnant during the clinical trial. (15) Patients with or suspected of having a malignant tumor, or patients with a history of malignant tumor except for the patients in whom recurrences have not been confirmed by routine observation after treatment. (16) Patients with hypothyroidism, hereditary muscular diseases (muscular dystrophy, etc.) or familial history of these diseases. Patients with history of drug-related muscular disorder. (17) Patients with drug abuse or alcoholic. (18) Patients who are ineligible in the opinion of the investigator.
研究者
相似试验
已完成
不适用
The Sakakibara Health Integrative Profile of Atherosclerotic-Carcinogenesis Hypothesis (SHIP-AC)CancersAtheroscleroses, CoronaryAtherosclerosis of ArteryNCT04198896Sakakibara Heart Institute8,856
已完成
不适用
Investigation of the progression of atherosclerosis and atherosclerotic risk factor in patients with diabetesDiabetesJPRN-UMIN000014765Division of diabetes, Mitsui Memorial Hospital700
招募中
1 期
Regression of atherosclerosis induced by life changing experience with psilocybiEUCTR2022-003381-21-CZPsyon, s.r.o.60
招募中
Unknown
An Exploratory Study of Atherosclerosis/Bleeding Risk Events in Patients Undergoing Percutaneous Coronary InterventioIschemic heart diseaseJPRN-UMIN000049264ihon University School of Medicine Department of Cardiology800
尚未招募
不适用
Analysis for regression of atherosclerosis in acute coronary syndrome patients after PCSK9 inhibitor therapy by using near-infrared spectroscopy and intravascular ultrasoundJPRN-UMIN000027238Kyoto Prefectural University of Medicine50